•Bioventix remains a specialist healthcareBusinessbuilt around the development and commercialisation of high-affinity monoclonal antibodies used in diagnostic tests. Recent company disclosures have kept attention on board changes, product performance and the durability of the mature product portfolio, while the shares have also shown relatively …
Oxford Nanopore develops sequencing technology that reads DNA and RNA by passing molecules through tiny pores and measuring changes in electrical current. Its devices range from pocket-sized sequencers to high-throughput systems, used in research, clinical diagnostics, biopharma and applied industries.
Shield's lead product is Accrufer, known as Feraccru in some markets, a non-salt oral iron therapy for adults with iron deficiency with or without anaemia. The product offers an alternative to traditional iron salts, which often cause gastrointestinal side effects, and to intravenous iron …
Bioventix creates antibodies that are used in blood tests run on large diagnostic analysers made by global healthcare companies. It earns money in two ways: by selling physical antibody supplies and by collecting royalties on tests that use its antibodies. Royalties make up the …
In an announcement released at 13:48 on 29 September 2026, Spire Healthcare Group plc (LSE:SPI) announced the publication of the scheme document for its proposedAcquisitionby Tulip UK Bidco Limited ("Bidco"). The announcement describes Bidco as "a newly formed company indirectly owned by a consortium …
NIOX Group published interim results for the six months ended 30 June 2026 at 07:00 on Tuesday, followed at 07:01 by details of a proposed tender offer and notice of general meeting.
Venture Life released its final results and a CEO succession update at 07:00 on 29 September 2026. The results cover a 17-month period to 31 May 2026, after the company moved its accounting reference date from 31 December. The comparative figures are for the …
In an announcement at 07:00 on 29 September 2026, HUTCHMED said that "AstraZeneca has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA")" for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib).
Oxford Biomedica shares rose 2.58% today to 517p, a gain of 13p, according to the market data provided, valuing the cell and gene therapy manufacturer at about £610 million.
In an announcement on 30 September 2026, the London Stock Exchange-listed drug developer reported a loss before taxation of £1,437,000 for the half year, compared with £1,621,000 in the first half of 2025. Cash and cash equivalents at 30 June 2026 were £659,000, down …